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Abstract
Cervical cancer is the fifth most common cancer in United States with more than 12,000
women diagnosed each year and more than 4,000 preventable deaths with minorities
disproportionally represented. Cervical cancer prevention strategies rarely focus on the
management of abnormal screening results. The purpose of this quality improvement
project was to standardize the management program for abnormal cervical cancer
screening results within an integrated health delivery system serving a large minority
community. The Plan-Do-Study-Act model guided a comprehensive program evaluation
with process improvement, including the creation of an electronic quality data reporting
tool to formalize the work process and a quality control and assurance program with
exception reports. The evaluation was completed with data to measure the timeliness of
abnormal results outreach and continued clinical management. The data were evaluated
over time with run charts. Also, an analysis of the data was done through pre- and posttest comparisons with 2-sample t tests to evaluate abnormal cervical cancer screening
management before and after the revisions. Although the project did not show a
statistically significant difference in the timeliness of outreach and follow-up of abnormal
cervical cancer screening results due to the limited data set, the run charts trended
positively for timeliness and consistent data reporting with no missed screening reports.
Effective cervical cancer screening includes the accurate and timely management of
abnormal results to reduce disparities in cervical cancer deaths. This project contributes
to positive social change by responding to the Healthy People 2020 goal to reduce the
incidence of cervical cancer deaths through a formal process to insure timely intervention
for abnormal results in a largely minority community.
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Section 1: Overview of the Evidence-Based Scholarly Project
Introduction
The risk of cervical cancer is most closely correlated with the presence of the
human papilloma virus (HPV) and previous abnormal Papanicolaou (Pap) smears, also
called Pap tests (Spence, Goggin, & Franco, 2007). Adhering to recommended cervical
cancer screening guidelines with cytology (Pap smear) has been shown to reduce the
incidence of invasive cervical cancer (Vaccarella, Lortet-Tieulent, Plummer, Franceschi,
& Bray, 2013; Vesco et al., 2011). The U.S. Preventive Services Task Force (USPSTF)
identified 15 studies that reported dramatic reductions in the incidence and mortality of
invasive cervical cancer (ICC) attributed to the increase in regular cervical cancer
screening (Vesco et al., 2011). Since 1955, there has been more than a 60% reduction in
the incidence and death rate of cervical cancer (National Institutes of Health [NIH],
2010). Despite the significant decline in cervical cancer deaths over the last 40 years,
more than 4,000 annually die in the United States from this treatable disease. According
to the Centers for Disease Control and Prevention (CDC), in 2014, 12,109 women were
diagnosed with cervical cancer and 4,092 women died from the disease (CDC, 2014).
The incidence of invasive cervical cancer varies with regards to race, ethnicity,
and age. Cervical cancers are higher in Black and Hispanic women compared to all other
races and ethnicities in the United States (CDC, 2014; Vesco et al., 2011). The overall
age-adjusted incidence rate of cervical cancer in the United States is 7.6/100,000 per
year. The incidence is highest among Black (9.0/100,000) and Hispanic (9.8/100,000)
women, compared to non-Hispanic White women (7.6/100,000; Kaiser Family
Foundation, 2015). Diagnosis of cervical cancer also increases with age. From 2004-
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2008, one half of total new cervical cancer cases occurred in women 35 to 55 years of age
(Vesco et al., 2011). There is a strong link between lack of routine cervical cancer
screening and the incidence of invasive cervical cancer as a U.S. Preventive Task Force
(USPTF) systematic review of studies done on women diagnosed with ICC shows that
more than half reported inadequate screening (Vesco et al., 2011).
The majority of cervical cancer prevention and reduction strategies are focused on
increased screening; however, proper management of abnormal results is also a
contributing factor to appropriate and timely intervention (Yabroff, Kerner, &
Mandelblatt, 2000). Identification of abnormal results, performed well by most accredited
healthcare organizations, is only the first step in the screening process. The reduction in
invasive cervical cancer is not possible without the next step: appropriate follow-up of
these abnormalities (Spence, Goggin, & Franco, 2007).
The organization selected for this project, hereafter referred to as A1 Organization
(pseudonym), has a robust, efficient, and effective cervical cancer screening program.
Although A1 Organization outperforms most industry screening benchmarks,
opportunities exist to enhance their current program – including improving the timely
notification of women identified with abnormal Pap smears and identifying barriers to
proper follow-up care. Incorporating evidence-based quality performance measures into
the quality monitoring process helps organizations to sustain improvement activities,
monitor effectiveness, and enable additional quality improvement (Maheshwari &
Janseen, 2013; McLaughlin, 2014).
A1 Organization has established guidelines to track abnormal results and ensure
timely follow-up; however, the current paper-based process for tracking quality at the
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time of this project was not standardized across the organization. Quality reports were
completed by hand using a standard form, but monitoring and reporting of quality metrics
and performance was inconsistently done throughout the three regional service lines. In
addition, this process monitored performance for the general patient population, but did
not stratify results based on patient demographics. This prevented the organization from
monitoring performance in specific populations in order to identify potential areas for
improvement. An identified current practice problem, the need for standardized
performance monitoring in A1 Organization’s current abnormal Pap smear results
coordination program, was addressed by this project.
Problem Statement
The purpose of the project was to assess, standardize, and improve the quality
monitoring and management of abnormal Pap smear results. This project was designed to
contribute to the prevention of invasive cervical cancer in women seeking services at an
integrated health care organization.
Program objectives
The objectives of the program were:
•

To standardize monitoring and reporting activities by electronically incorporating
current quality metrics for the organization’s abnormal Pap smear management
program using the electronic health record system.

•

To develop a centrally managed electronic quality report of the organizationspecific quality metrics for abnormal Pap smear management.

•

To explore the possibilities of stratifying performance outcomes based on race,
ethnicity, and age for future reporting opportunities.
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•

To improve timeliness of abnormal Pap smear notification and follow-up for sites
performing below quality measure targets through use of electronic monthly
and/or quarterly Pap Tracking quality reports.

Defining the Project Question
A good project question should be clearly identified, measurable, and promote
evidence-based practice (Terry, 2012). Using the PICOT method to format the
improvement questions leads to an appropriate focus for an implementation project.
PICOT stands for: patient or population, issue or intervention, comparison, outcome, and
time (Elkins, 2010; Fineout-Overholt & Johnston, 2005). The elements of the research
problem are therefore described below using the PICOT method:
•

P: Problem – Lack of consistent/standardized performance monitoring in the
organization’s cervical cancer screening surveillance (CCCS) or “Pap Tracking”
program.

•

Population – OBGYN providers, nurses, and leadership.

•

I: Intervention – Implement electronic monitoring of quality metrics for
management of abnormal Pap smears.

•

C: Comparison – Timeliness of abnormal Pap smear results management prior to
electronic quality metric monitoring; Not all sites are meeting their target of
reviewing abnormal results within 30 days.

•

O: Outcome – Demonstrate consistent performance monitoring of abnormal Pap
smear management through region-wide use of standardized monthly and
quarterly reports, and; Demonstrate improved performance in timeliness of
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abnormal Pap smear management as defined by current evidence-based practices
and organization clinical guidelines.
•

T: Time – Approximately three months from implementation of electronic quality
monitoring.
Based on this identified practice problem, the project question was:

Will the implementation of an electronic quality monitoring tool for the CCCS program
result in improvements in quality outcomes at the project site?
The Social Significance of Abnormal Pap Smear Management
Cervical cancer deaths have decreased significantly as a result of increased
cervical cancer screening rates (CDC, 2014); however, invasive cervical cancer remains
the fifth most common cancer in U.S. women and the second most common cancer for
women in the world (CDC, 2014; Spence, Goggin, & Franco, 2007). Invasive cervical
cancer is preventable, but only with timely screening and follow-up care (Spence,
Goggin, & Franco, 2007). Despite improvements in cervical cancer screening, women
continue to develop invasive cervical cancer.
There are also significant disparities in cervical cancer rates among certain
populations depending on their age, race, and ethnic background. In the United States,
African American and Hispanic women continue to have the highest incidence of cervical
cancer with the rate being 9.0/100,000 and 9.8/100,000 respectively, compared to
7.3/100,000 for White women (CDC, 2014; Kaiser Family Foundation, 2015). There is
also a disparity in death rates from cervical cancer, with African American women
having the highest rate at 4.0/100,000, compared to 2.6/100,000 for Hispanic women and
2.1/100,000 for White women (Kaiser Family Foundation, 2015). Invasive cervical
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cancer rates vary by age as well, increasing with age and peaking between the ages of 35
and 55 years old (Vesco et al., 2011). Though the United States has reduced the number
of deaths from invasive cervical cancer, the disease continues to pose a significant public
health issue to vulnerable populations (Vesco et al., 2011).
The Healthy People 2020 (2014) initiative established evidence-based objectives
for improving the health of the U.S. people over the next decade. Regarding cervical
cancer, national target for reducing cervical cancer deaths to 7.5 new cases of invasive
cervical cancer per 100,000 – a 10% improvement over the baseline rate of 8.3 cases per
100,000 (Health People 2020, 2014). Developing programs to improve management of
abnormal Pap smear results combined with U.S. national efforts to increase cervical
cancer screening will help to achieve the Health People 2020 target and reduce disparities
in cervical cancer deaths.
Financial Impact of Cervical Cancer
Although rates of cervical cancer are steadily declining, the disease continues to
impose a significant financial burden in the United States. Estimates for the annual
economic burden of cervical cancer ranges from $300-400 million to as high as $1.55
billion (Insinga, Dasbach, & Elbasha, 2005; Mariotto, Yabroff, Shao, Feuer, & Brown,
2011). Per person, the estimated four-year cost for cervical cancer is $18,799 (Insinga,
Ye, Singhal, & Carides, 2008). In 2010, the estimated aggregated medical costs of
cervical cancer treatment during the initial year of diagnosis totaled $492,000,000
(Mariotto et al., 2011). Treatment beyond one year of diagnosis incurred costs of
$368,000,000 per year, with an additional $685,000,000 during the last year of life
(Mariotto et al., 2011; National Cancer Institute, 2014).
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The costs of cervical cancer extend beyond treatment costs. For example,
productivity loss due to cervical cancer deaths is estimated to be $1.3 billion per year
(Insinga, 2006). If the rate of cervical cancer remains constant, medical care costs are
expected to continue rise (National Cancer Institute, 2012). Diagnosing and treating
cervical cancer in the early stages is important because this increases the survival rate,
decreases morbidity, and significantly reduces costs related to care and lost productivity
(Subramanian et al., 2010).
Assumptions and Limitations
With increased cervical cancer screening and HPV vaccination rates, I assumed
that improving timeliness of follow-up for abnormal results would further reduce the rate
of invasive cervical cancer. While electronic quality monitoring has been shown to
improve quality outcomes and reduce timeliness of interventions (Dupuis et al., 2010),
the literature for this project did not identify any studies directly linking improved
monitoring of abnormal results to reduced rates of invasive cervical cancer. Also, this
project did not take into account factors influencing women’s adherence to recommended
follow-up plan once contact is made for abnormal results. The target population for the
project had access to comprehensive cervical cancer screening services as part of their
insurance plan. The interventions developed through this project may not be applicable or
may be limited if trying to improve the quality of cervical cancer prevention programs in
settings where patients have limited access to care or lack of health care insurance (e.g.,
public health centers, free clinics, or community-based clinics).
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Summary
Cervical cancer, though preventable, continues to affect thousands of women in
the United States (Vesco et al., 2011). After prevention of HPV infection through
vaccination, regular screening and early treatment of abnormal Pap smears are the best
ways to prevent cervical cancer and related deaths (Subramanian et al., 2010).
Identification of precancerous and cancerous lesions is only the beginning step in the
screening process. Nationwide cervical cancer screening efforts will not be successful
without adequate triage and appropriate follow-up of abnormal results (Chase, Kalouyan,
DiSaia, 2009; Spence, Goggin, & Franco, 2007).
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Section 2: Review of Scholarly Evidence
Literature Search Strategy
The initial literature review of the problem consisted of searches using several
databases. The databases used were CINAHL, MEDLINE, Pubmed, ProQuest, and
ScienceDirect. Key words related to abnormal Pap smear results, abnormal results
management, and quality improvement were initially used, but returned only several
articles related to the subject. The search was broadened and expanded to include the
words “cervical cancer screening” and “quality improvement”, which provided more
general articles, but these articles had minimal relevance. The majority of the articles
dealt with improving cervical cancer screening rates, as opposed to management of
abnormal results. In order to find additional reference articles for inclusion, an individual
review and reference search for each included article was conducted. In the end, a total of
nine articles related to management of abnormal cervical cancer screening results were
selected for review (Burack, Gimotty, Simon, Moncrease, & Dews, 2003; Chase,
Kalouyan, & DiSaia, 2009; Dupuis et al., 2010; Hermens et al., 2005; Kupets & Paszat,
2010; Leyden et al., 2005; Massad et al., 2013; Spence, Goggin, & Franco, 2007;
Yabroff, Kerner, & Mandelblatt, 2000).
Cervical Cancer
Cervical cancer is a well understood neoplasm (Vesco et al., 2011); hence, the
disease is preventable with early detection and treatment of premalignant cervical
changes (Subramanian et al., 2010). The risk of cervical cancer is most closely correlated
to the presence of the Human Papilloma Virus (HPV) and abnormal Pap smear results.
HPV is responsible for about 91% of cervical cancers (CDC, 2014). Even once
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diagnosed, survival rates for cervical cancer are significantly greater if caught before the
disease progresses to the uterus or other organs of the body. Because cervical cancer
progresses slowly in the initial stages, early identification and treatment of cancerous and
precancerous cervical lesions is the key to survival (Moyer, 2012; Vesco et al., 2011).
Abnormal Pap Smear Management
Cervical cytology screening (i.e., Pap smears) is both cost-efficient and sensitive
at detecting precancerous and cancerous cervical cells (Vesco et al., 2011). Cytology
screening with or without HPV testing is the technique of choice for cervical cancer
screening in the United States (Massad et al., 2013; Moyer, 2012; Vesco et al., 2011).
The U.S. Preventive Services Task Force (USPSTF) recommends screening for cervical
cancer in low-risk women age 21 to 65 years with a Pap smear every three to five years
(Vesco et al., 2011). The Healthcare Effectiveness Data and Information Set (HEDIS) are
a set of quality performance measures determined by the National Committee for Quality
Assurance (NCQA) and are used as an external benchmark for comparison by many
health care organizations (NCQA, n.d.). Current HEDIS measures for cervical cancer
screening determine the number of eligible women between 21-64 years of age who had
documented cervical cytology every three years or every five years for women 30-64
years old with cervical cytology/HPV co-testing (NCQA, n.d.). Many health care
organizations in the U.S. establish their guidelines for cervical cancer screening based on
current USPSTF recommendations and/or HEDIS measures.
A comprehensive cervical cancer-screening program should not only focus on
early diagnosis, but it should incorporate strategies to ensure appropriate follow-up
(Hermens et al., 2005). Lack of screening, improper or poor screening technique, and
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lack of adequate follow-up all influence the development of invasive cervical cancer in
women (Spence, Goggin, & Franco, 2007). The majority of cervical cancer cases are in
women who were never screened before (Leyden et al., 2005; Spence, Goggin, & Franco,
2007; Vesco et al., 2011). A small percentage of invasive cervical cancers are a result of
a failure in the screening process. A retrospective cohort study of patients from seven
U.S. health plans, who were diagnosed with cervical cancer between 1995 and 2000,
showed that 32% of these patients had normal Pap smear results preceding their diagnosis
of cervical cancer (Leyden et al., 2005). Although a lack of screening is a major risk
factor for advanced cervical cancer, an estimated 12% of all invasive cervical cancers in
the United States, Canada, Australia, and Europe have been attributed to poor follow-up
of abnormal results (Spence, Goggin, & Franco, 2007).
When an abnormal Pap smear is identified, the procedure of choice for diagnosing
cervical cancer and precancerous cervical lesions is performing a biopsy of the cervix
during a colposcopy. A colposcopy is a medical procedure to examine the tissues of the
cervix using special equipment called a colposcope. The colposcope magnifies and
illuminates the tissues of the cervix, vagina, and vulva, permitting the user to distinguish
abnormal cells from normal cells. Once identified, the abnormal cells are biopsied and
sent to pathology for a definitive diagnosis (Chase, Kalouyan, & DiSaia, 2009).
The standards for treatment of clinically diagnosed precancerous lesions or
cervical cancer are based on the current American Society for Colposcopy and Cervical
Pathology (ASCCP) Consensus Guidelines. Revised in 2012, the ASCCP Consensus
Guidelines include evidence-based guidelines for the management of abnormal Pap tests,
cervical intraepithelial neoplasia (CIN), and cervical cancer or adenocarcinoma in situ

12

(AIS; Massad et al., 2013). Based on the guidelines, algorithms have been established to
aid health care providers in triaging and managing abnormal cytology results (Chase,
Kalouyan, & DiSaia, 2009).
Factors That Contribute to Inadequate Follow-up
Failure rates for follow up of abnormal cervical cancer screening results are as
high as 50% (Hermens et al., 2005). Several studies (Kupets & Paszat, 2010; Leyden et
al., 2005; Spence, Goggin, & Franco, 2007; Yabroff, Kerner, & Mandelblatt, 2000)
attempted to determine contributable factors to inadequate follow-up of abnormal Pap
smear results. From these studies, several patient and provider characteristics were
identified to be relevant to the inadequate follow-up. The patient-related factors include
fear, comorbidities, understanding of their condition, understanding of the importance of
follow-up, trust with their provider, and low-income or minority women (Kupets &
Paszat, 2010; Spence, Goggin, & Franco, 2007). The provider-related factors include
inadequate tracking of results, poor communication to patients, and poor adherence to
clinical guidelines (Kupets & Paszat, 2010). Furthermore, in a population-based study
(n=43,792) over a 5-year period, Kupets and Paszat (2010) reported approximately 26%
of women with abnormal cytology results were not appropriately evaluated for as long as
two years after the screening.
Literature Examples for Successful Follow-up
Most studies regarding abnormal Pap smear follow-up are designed to improve
patient compliance, as opposed to addressing provider factors (Hermens et al., 2005).
Prompt physician communication to patients and automatic patient reminders, similar to
what is commonly used to communicate mammogram results to women, increase follow-
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up of abnormal cancer screenings (Burack, Gimotty, Simon, Moncrease, & Dews, 2003;
Yabroff, Kerner, & Mandelblatt, 2000). For example, a provider-targeted study by
Hermens et al. (2005) demonstrated that an automatic management system providing
reminders to providers of patients who did not complete an appropriate follow-up was
more successful than a system that relied on the provider alone to track patients. Another
study found that an electronic health record-based tracking system increased the
timeliness of interventions for abnormal Pap test results and decreased the time from
diagnosis to resolution of abnormal results (Depuis et al., 2010).
Literature Support for Quality Monitoring
From a quality improvement perspective, research that demonstrates continuous
collection and analysis of quality data significantly improves clinical performance and
outcomes (Curcin, Woodcock, Poots, Majeed, & Bell, 2014). This is the reason why the
Agency for Healthcare Research and Quality (AHRQ) recommends incorporating
outcome and performance measurements to improve quality and accountability (Institute
of Medicine [IOM], 2001). AHRQ also supports utilizing information technologies to
improve access to clinical information (IOM, 2001).
Quality tracking and quality reports can help provide a snapshot organizational
performance to leadership, administration, and clinical staff. The information used from
quality reports can guide the organization in prioritizing and focusing efforts in order to
meet internal and external benchmarks, as well as help improve overall patient care
(Wyatt, 2004). Quality dashboards provide metrics for key performance indicators to
provide an overview of how well an organization, department, or program is doing. They
not only monitor how well an organization is performing, they can be used to help
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improve performance setting goals and establishing timelines to meet these goals (Wyatt,
2004). Whereas a balanced scorecard shows past metrics data, a dashboard delivers data
more recent data (Frith, Anderson, & Sewell, 2010). This provides access to the most
current metric data and can allow leadership to implement changes to address these
metrics in a timely manner. Using a quality dashboard can provide quality information
that can be utilized to make decisions to improve organizational performance and
ultimately enable them to satisfy their goals. Data from quality dashboards can be used
by physicians and nursing frontline staff to guide the care that they provide and increase
their accountability for improving outcomes, regardless of their organizational roles
(Frith, Anderson, & Sewell, 2010).
Successful programs are both effective and financially viable (Hodges & Videto,
2011). While the current climate of health care is focusing on quality improvement,
leadership is still charged with proving some financial benefits from quality-improvement
projects. Demonstrating a return of investment on quality initiatives can be a difficult, if
not impossible task to accomplish, especially without utilizing methods to measure the
financial impact (Coehlo & Vilares, 2010). Conducting a quality-improvement project
within an established quality-monitoring program can result in potential financial benefits
as well. Studies have shown that quality-improvement projects that focus on improving
internal processes can have a positive financial impact through cost reduction (Rust,
Moorman, & Dickson, 2002).
Theoretical Framework
Health care organizations should continuously evaluate established processes to
achieve the best outcomes possible. Total quality management theory (TQM) describes
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“the continual method, techniques and technical of sustaining continuous quality
improvement” in order to improve the overall performance of a company (Bon &
Mustafa, 2013, p. 518). Grounded in the teachings of William Edwards Deming and
Deming’s theory of management, TQM provides a framework for continuous
performance improvement in all organizational areas and levels. TQM theory proposes a
holistic approach to quality improvement that encompasses three principles: Customer
focus, continuous improvement, and teamwork (Zehir, Ertosun, Zehir, & Muceldilli,
2012). Use of TQM as a framework for quality improvement has been shown to improve
quality performance and support innovation (Bon & Mustafa, 2013; Zehir, Ertosun,
Zehir, & Muceldilli, 2012).
Evidence-Based Practice Model
The project was implemented using the PDSA or Shewart cycle model. In today’s
rapidly changing health care landscape, more quality improvement tools are being used to
assist in implementing evidence-based interventions (Siriwardena, 2009). The evidencebased practice PDSA cycle model was used to guide this project. The PDSA model is a
quality improvement model that provides a simple, systematic approach to addressing a
performance problem (Kelly, 2011). Developed by Walter Shewhart and Edward
Deming, this model was designed for use in the industrial field (Taylor et al., 2013).
PDSA stands for “Plan”, “Do”, “Study”, and “Act”, which are the four cyclical steps of
the model. The PDSA model is a useful tool in investigating current processes while
implementing evidence-based change in a rapid manner (Siriwardena, 2009). Kelly
(2013) advised answering three questions before implementing the PDSA model:
1. What are we trying to accomplish?
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2. How will we know that a change is an improvement? and
3. What change can we make that will result in an improvement? (p. 141)

The cycle begins with the Plan phase. During the Plan phase, needs relating to the
practice problem will be identified and prioritized, and then used to develop a plan for
addressing the problem. During the Do phase, the developed plan will be implemented.
The Study or Check phase involves analyzing outcomes and metrics before and after the
intervention to determine if there was an effect. If the intervention is proven to be
effective, it is incorporated throughout the organization.
Successful use of PDSA cycles allows interventions to be tested on a smaller
scale, which “enables rapid assessment and provides flexibility to adapt the change
according to feedback to ensure fit-for-purpose solutions are developed” (Taylor et al.,
2013, p. 291). This enables changes to be tested, evaluated, and modified - with minimal
risks – before implementing system-wide. The PDSA cycle approach has been shown to
lead to significant improvement in care (Taylor et al., 2013). The PDSA cycle was
therefore chosen to provide a structured framework to rapidly design and implement the
proposed performance improvement initiative. The model was also used to continuously
evaluate whether the initiative was effective and aligned with the organization’s
performance objectives.
Summary
In order for programs to run effectively, it is important for organizations to have
access to current, real-time data. This allows stakeholders and managers to accurately
monitor performance and utilize the data to make decisions to improve performance and
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satisfy program objectives and goals (McLaughlin, 2014; Wyatt, 2004). Performance
reporting and monitoring allows for increased program transparency, increased
accountability of programs, and increased support for maintaining, expanding, or
restructuring programs (Inamdar, Kaplan, & Reynolds, 2002). Quality reports can be
used to identify the patterns within the program to help identify areas of excellence and
diagnose areas that need improvement. Establishing timely tracking/response of abnormal
Pap smear results as a routinely monitored performance measure can help organizations
to improve their management of adequate follow-up (McLaughlin, 2014).
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Section 3: Approach
Overview of Methodology
The site organization, referred to as A1 Organization (pseudonym), has
established guidelines and criteria for monitoring performance and quality of their
Cervical Cancer Screening Surveillance Program. At the time of this project, the
organization performed quality monitoring of the program using a paper-based method.
While the organization generates many quality reports using data from the electronic
health record (EHR) system, abnormal Pap smear results were tracked using an older
tracking system that has limited interoperability and interfacing abilities with the current
EHR. This internal tracking system identified and monitored patients with abnormal Pap
smear results based on the following diagnoses:
•

High Risk Human Papilloma Virus (HPV) Detected;

•

Atypical Squamous Cells of Undetermined Significance (ASCUS);

•

Low-Grade Squamous Intraepithelial Lesion (LSIL) encompassing HPV, Mild
DysplasiaCIN-1;

•

High-Grade Squamous Intraepithelial Lesion (HSIL) encompassing moderate and
severe dysplasia, Carcinoma in Situ (CIS), Cervical Intraepithelial Neoplasia
(CIN) CIN-2, CIN-3;

•

Squamous Cell Carcinoma; and

•

Glandular Cells encompassing atypical, suspicious for neoplasia, and
endocervical adenocarcinoma in situ.
The quality reports were completed by the registered nurses (RN) assigned to

program. The organization is broken down into three regions: District of Columbia &
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Southern Maryland (DCSM), Northern Virginia (NOVA), and Baltimore (BALT). Each
region has one or two nurses who are responsible for tracking abnormal Pap smear results
of the patients within those regions only. The responsible Pap Tracking RN uses data
generated from the older tracking system and incorporates them into two paper reports.
In this system, the monthly handwritten report contains information regarding the
number of unaddressed abnormal Pap smear results called the “Open Items” report. The
quarterly report, titled the “Pending Items” reports, provides information abnormal results
that were addressed by the clinical team (i.e., contact to the patient was initiated and an
appointment was scheduled), but the patient did not receive the appropriate follow-up.
The current organization goal at the time of this project was to have 100% of the
abnormal Pap smear results addressed by the RN, including the appropriate appointments
scheduled within 30 days; and the appropriate follow-up, as determined by the
organization’s evidence-based guidelines, in less than 90 days.
In this project, the intervention included reviewing and/or redefining established
quality metrics, capturing the identified metrics from the organization-specific tracking
system, and incorporating metrics into an electronic performance quality report. While
leaders monitor the macro-level performance, gaps in care for certain populations are not
visible in the aggregate results. As such, options were explored to determine if the report
could be stratified by demographics (e.g., race, age, geographic location, etc.) selected by
the organization to also monitor micro-level results. Stratifying quality performance data
by demographics can identify shortfalls in specific populations, even when overall
performance is satisfactory, and clearly present areas for improvement.
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The anticipated outcome from the new process was that transparency and
feedback offered by the new quality reports would positively impact overall performance
and lead to improvements for specific populations. The objectives were to learn how the
program served specific populations, identify potential areas for process improvement,
and achieve the stated performance goals for abnormal Pap smear management.
The timeframe for the project objectives are listed below:
•

Establish electronic monitoring of quality metrics (12 weeks)
o Evaluate Baseline Quality Improvement Data (7 days)
o Review/Edit/Confirm Quality Metrics for Pap Tracking Program (14 days)
o Collaborate with clinical quality team to create an electronic quality report
(6 weeks)
o Investigate options to stratify electronic report by demographics (9 weeks)

•

Demonstrate improvement in timeliness of abnormal Pap smear result
notification and follow-up (12 weeks)
o Communicate overview and purpose of new electronic Pap Tracking
Quality Report to Service Line (2 weeks)
o Implement electronic monthly quality reports (12 weeks)
o Perform chart reviews of site performing under target to identify possible
barriers to care coordination and opportunities for improvement (2 weeks)
o Evaluate outcomes postintervention to demonstrate effectiveness (1 week)

Data Collection
Continuous data collection and concurrent data analysis are critical attributes for a
functional quality improvement program (Curcin et al., 2014). Also, systematic processes
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to measure and track quality improvement processes can validate the effectiveness or
ineffectiveness of interventions as well as the sustainability (Varkey, Reller, & Resar,
2007). The data collected were the quality metrics established by the organization: the
number of abnormal results that had not been reviewed after more than 30 and 60 days,
and the number of patients during the previous 90 days who were notified, but still had
not returned for follow-up.
For this DNP project, data collection was conducted using the developed
electronic reports. Human subjects were not used and no identifiable patient information
was included in these reports. A simple time-series study design was used to measure the
effects pre- and post-implementation of the electronic reports. This quasi-experimental
research design was selected because a true experimental design was not feasible in this
setting. A simple time-series design involves “the collection of data over an extended
period of time and the introduction of an experimental treatment during the data
collection process” (Terry, 2012, p. 76). For this project, a single group pretest/posttest
design was used. A baseline measurement of quality data was obtained prior to
implementation of the program using the current process. Once the electronic report was
been created, quality data were measured in the beginning and three months after
implementing electronic quality reports. All data were presented in aggregate form only.
One of the limitations of this study design was that there was no random sampling
of subjects (i.e., patients with abnormal Pap smears). Another limitation was the lack of a
control group to determine if any changes to performance are truly a result of the
intervention rather than external factors. The lack of random sampling or a control group
increases confounding bias and reduces internal validity (Terry, 2012).
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Analysis Method
A two-sample t test was used to measure the differences in mean quality
outcomes before and after implementing electronic quality reports. A two-sample t test
analysis “makes inferences about the equality of two population means, based on two
sample means” (Polit, 2010, p. 133). Since the data involved comparing performance
outcomes of the same group pre- and post-intervention, a dependent groups t test was
required. Because of the small data sample, run charts were used in addition to t tests to
show the quality data trends over time.
Summary
The project, while designed to improve patient clinical outcomes, focused on
improving clinical staff performance and process improvement. Due to time constraints
and limitations of the project setting, a single group comparison, simple time-series study
was conducted. The selected study design was limited by threats to internal validity. Run
charts were also used to identify any trends in quality data after implementation. In spite
of the limitations to the selected study design, my intent was to demonstrate that any
significant improvement in quality performance was attributable to the implementation of
standardized monitoring using electronic quality reports.
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Section 4: Findings
Introduction
While working with leadership within A1 Organization’s (pseudonym) maternalchild health service line, the decision was made to develop an evidence-based quality
improvement initiative to improve their longstanding program for monitoring abnormal
cervical cancer screening results. The purpose of the quality-improvement project was to
standardize the program’s quality metrics and monitoring, explore capabilities for
stratifying the quality data by patient demographics, develop an electronic quality
reporting tool to be used throughout the organization, and improve timeliness of followup for abnormal cervical cancer screening results.
Results
As part of the quality improvement initiative, key stakeholders within the Cervical
Cancer Surveillance Program (CCSP) resumed regular meetings to review the quality of
the program. I worked within the CCSP’s Regional Pap Quality Meeting to develop and
implement the approved DNP project. In reviewing the organization’s process for quality
monitoring and reporting, different regions were found to have the same quality metrics.
However, each region monitored and reported the data at different intervals using
different reporting forms. With conversation and the intention for increased collaboration,
the group agreed to continue using the established quality metrics and to unify the
reporting to generate monthly quality reports for all regions.
I used the old quality metrics and reports to build a new electronically formatted
report to be used by the nurses in the program. For nursing leadership, a report was
created to show the data trends for up to one year at a time. The reports were designed to
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improve ease of use and reduce errors by providing automatic calculations of percentages
and totals. They also automatically displayed the data with certain visual characteristics
to show the user immediately which centers did not meet the threshold targets. An added
feature to the reports was that they automatically generated charts of the quality metrics
once the data were updated. This allowed nurses and leadership to visualize the data
trends for the month and over time.
Once the reports were created, they were presented at the Regional Pap Quality
Workgroup and approved for use by its members. In order to analyze whether use of the
newly implemented electronic reports helped to improve timely outreach and follow-up, I
compared the quality data from the first and second quarter of 2016 to the data from the
reports generated in 2015. The reports were piloted in one of A1 Organization’s three
service areas: Baltimore, Northern Virginia, and District of Columbia & Suburban
Maryland (DCSM). However, the only available data came from the DCSM service area
and were thus utilized for this project.
By comparing the data from the Open Items Report (OIR) on how soon outreach
was done on abnormal results, I determined that the average compliance rate for all of the
medical centers combined was 98% in 2015. For 2016, this number decreased to 95%,
meaning that more medical centers were not meeting their goals and were notifying
patients more than 30 days after the results were first available. A second report called
the Pending Items Report (PIR) was also used. The PIR shows the number of abnormal
results that were addressed by the health care team or PTN, but are still awaiting
appropriate follow-up (e.g., colposcopy). Comparing the PIR from 2015 to the first and
second quarter of 2016, more medical centers had patients that still had not received the
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appropriate follow-up for their abnormal Pap smear results by 30 days after notification
than had previously been in 2015. The data analysis did not support the project’s
hypothesis that implementation of a standardized electronic report tool will improve
quality for this program.
Data samples from an aggregate of 12 months were used: six nonconsecutive
months in 2015 and six consecutive months in 2016. (This was due in part to the quality
reports having not been consistently run in 2015, resulting in only 6 months of data being
available.) Using the OIR and PIR data from 2015 and 2016, I conducted a two-sample t
test to analyze the results. Both t tests assumed unequal variances. For the OIR report
(Table 1), the mean compliance was 98.4% for 2015 compared to 93.9%. The twosample t test gave a t-statistic of 2.024 with 6 degrees of freedom (df). Using a
significance level (a) of 0.05, the p-value is .089 and the t-value for the data is 2.447.
This shows that there was no significant difference between the two data sample means.
After performing a t test for the PIR report, the results were similar (Table 2). The mean
PIR compliance rate was 98.2% in 2015 and 95.1% in 2016. The t-test statistic was 6.484
with a df of 10. Using an a = 0.05 and a p-value of 7.04 and the critical value is 2.31. As a
result, this also demonstrated no significant difference in the means for the PIR quality
data.
Because of the small data sample, run charts (Tables 3-6) were created to show
the overall trend in data from the previous year until May 2016. The data trend for 2016
showed that compliance had dropped slightly from the previous year for both the OIR
and the PIR. As noted before, the average overall OIR compliance for the region was
93.9% in 2016 compared to 98.4% in 2015. For the PIR, the average compliance for the
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region was 98.2% in 2015, but had dropped to 95.1% for the 2016 data. Overall, the
results and data analysis did not support the objective of improving the program’s quality
scores.
Table 1
Data Analysis of Open Items Report (OIR)
OIR Data Analysis
t test: Two-Sample Assuming Unequal Variances
Sample Size
SEM
2015
Data
M
Variance
Observations
Hypothesized M Difference
df
t Statistic
P(T<=t) two-tail
t Critical two-tail

12
1.2429
2016
Data

0.984028 0.939583
0.000297 0.002596
6
6
0
6
2.024003
0.089403
2.446912
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Table 2
Data analysis of the Pending Items Report (PIR)
PIR Data Analysis
t test: Two-Sample Assuming Unequal Variances
Sample Size
SEM
2015
Data
M
Variance
Observations
Hypothesized M Difference
df
t Statistic
P(T<=t) two-tail
t Critical two-tail

12
0.51484
2016
Data

0.981806 0.951111
5.96E-05 7.49E-05
6
6
0
10
6.483755
7.04E-05
2.228139
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Figure 1. Graph of the data trends for the monthly OIR compliance rate of each medical
center that reported in 2015. The OIR is the number of number of abnormal cervical
cancer screening results that were addressed (i.e., outreach) within 30 days or less.
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Figure 2. Graph of the data trends for the monthly OIR compliance rate of each medical
center that reported from January-June 2016. The OIR is the number of number of
abnormal cervical cancer screening results that were addressed (i.e., outreach) within 30
days or less.
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Figure 3. Graph of the data trends for the monthly PIR compliance rate of each medical
center that reported in 2015. The PIR is the number of number of abnormal cervical
cancer screening results that were addressed (i.e., outreach) by the health care team, but
were still awaiting appropriate follow-up (e.g., colposcopy, repeat pap, cryosurgery, etc.).
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Figure 4. Graph of the data trends for monthly PIR compliance rate of each medical
center that reported from January-June 2016. The PIR is the number of number of
abnormal cervical cancer screening results that were addressed (i.e., outreach) by the
health care team, but were still awaiting appropriate follow-up (e.g., colposcopy, repeat
pap, cryosurgery, etc.).
Discussion
Organizational decisions also had an effect on meeting one of the project
objectives. A1 Organization decided to phase out the outdated Pap smear results tracking
system that they currently use and build a new tracking program within their electronic
health record. The tentative go-live date for this new system is sometime in 2017.
Currently, the organization is still in the process of developing the new program and
working out kinks. Because of the impending plan to retire the presently used, but
outdated program, along with uncertainty regarding deployment of the new program and
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its capabilities, it was decided by administrative leadership not to explore options for
stratifying data by patient demographics until the new system is launched.
Operational activities within the service line created another variable that affected
quality data. During the project, the organization launched an upgrade to the lab result
reports function of the electronic health record. The upgrade led to a delay in receiving
lab results as it required an additional step to order the HPV test. This greatly impacted
the PTN’s workflow causing an increase in time to outreach and documentation of
follow-up. Additionally, because the pilot region was already using a different workflow
for pap tracking outreach than the other two regions, their nurses reported more
challenges with providing timely outreach after the upgrade which led to a greater impact
on their quality outcomes. Although there were several operational and departmental
factors involved that had a possible negative effect on project outcomes, the project
benefited the organization by creating a useful tool to monitor quality data and by
standardizing and facilitating quality improvement activities across the three service
areas. My professional opinion is that with more time to monitor and collect data, the
project will lead to significant improvement on overall quality metrics.
Strengths and Limitations
This project was deemed a Quality-improvement project by the IRB and received
an expedited approval. Though quality meetings and information was shared across the
organization, the quality tool was piloted in one service area to allow for faster
implementation and evaluation. The electronic reports, while not showing an initial
positive effect on quality outcomes, allowed the quality workgroup to review data trends
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(short-term and long-term) and quickly identify sites that may need a more detailed
investigation to determine possible barriers or areas for improvement.
A limitation noted in this project was inconsistent monitoring conducted by the
region selected. As a result, the service area had data missing for several months. Another
limitation noted was related to the current monitoring system which did not allow for
reports to be run on past data. I was left to complete the analysis with data from only six
months of the previous year and compare it to data from the first six months of 2016.
Since the 2015 data were incomplete, it was difficult to ascertain the potential impact of
the missing data on the project outcomes. Because of time constraints related to the
program, the collection and analysis of data was done relatively quickly. In my
professional opinion, time was also a limitation in demonstrating a meaningful impact on
improving quality metrics after using the reporting tool.
Implications for Practice
Though early results of the project did not support using electronic quality reports
to improve quality outcomes, it did help to standardize quality reporting procedures and
streamline quality improvement activities for this program. Whereas data collection was
inconsistent and incomplete throughout 2015, the selected service area reported timely
quality data for the first half of 2016. The PDSA model selected for the project can be
applied to other population care management programs (i.e., breast cancer screening) to
implement quality-based initiatives. The organization can summarize best practices
developed from its quality workgroup and share them with their health care partners in
the community. More importantly, the lessons learned from this project can help health
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care organizations to increase accountability and meaningful use of health care programs
while promoting continual improvement in multiple areas.
Analysis of Self
The planning, development, and implementation of my scholarly DNP project has
been a critical introduction to my role as a future DNP nurse. All of my didactic courses
and required practicum hours helped to prepare me for some of the challenges of
incorporating evidence-based practice in today’s dynamic health care setting. Although I
have spent the majority of my 18-year nursing experience in various leadership positions,
my journey through this program has rewarded me with additional knowledge and skills
needed to advance in my career as an advanced practice nurse.
Summary
Cervical cancer, while on a steady decline since implementing routine cervical
cancer screening in the United States, still continues to affect thousands of women and
results in hundreds of preventable deaths each year (CDC, 2014; Vesco et al., 2011).
Screening for cervical cancer, while arguably the most important step in preventing
invasive cervical cancer, is not effective alone. Appropriate follow-ups such as
colposcopies are needed to address any detected abnormalities and prevent progression to
invasive disease (Spence, Goggin, & Franco, 2007). While the target health care
organization for this project has long utilized a system to ensure timely notification and
intervention for abnormal cervical cancer screening results, the quality and performance
of the program was not being consistently monitored across the board.
The purpose of this project was to standardize the program’s quality metrics and
monitoring, explore capabilities for stratifying the quality data by patient demographics,
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develop an electronic quality reporting tool to be used throughout the organization, and
improve timeliness of follow-up for abnormal cervical cancer screening results. However,
project implementation was constrained by time and other major initiatives within the
organization. In addition, the project design did not permit the data segregation based on
patient demographics which might have demonstrate improvement in the quality scores
for specific segments.
The project also moved the quality monitoring practices to be standardized
throughout the program and helped to improve compliance with nursing quality
protocols. Furthermore, the program led to the development of an electronic quality
reporting tool to be utilized in all regions. This tool was centrally managed and can be
easily shared within the program, distributed across the service line, and disseminated out
to executive leadership. Overall, this quality-improvement project can be used as a model
with other population care-based programs to establish and evaluate quality metrics and
monitoring procedures to be employed as a way to promote continuous quality
improvement in any health care setting.
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Appendix: Example of Quality Reporting Tool
Month

Location 1 Location 2 Location 3 Location 4 Location 5 Location 6 Location 7 Location 8 Location 9 Location 10 Location 11 Location 12 2015
Quality
Data
Trends
Total

JAN
FEB
MAR
APR
98%
99%
MAY
95%
100%
JUN
97%
100%
JULY
AUG
SEPT
100%
97%
OCT
95%
96%
NOV
100%
98%
DEC
Overall Compliance
*Red Highlight = Action plan required.

100%
95%
100%

100%
100%
100%

100%
97%
99%

100%
100%
100%

100%
98%
100%

100%
95%
100%

100%
95%
100%

100%
95%
100%

100%
100%
100%

99%
95%
100%

100%
97%
100%

100%
100%
100%

100%
99%
100%

100%
98%
100%

100%
80%
100%

100%
96%
100%

96%
100%
100%

100%
86%
100%

100%
100%
100%

96%
96%
99%

100%
100%
96%

99%
96%
99%
98%
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Section 5: Scholarly Product-Manuscript Submission Draft
Cervical Cancer Prevention Screening: A Quality Improvement Project to Reduce
Variation and Increase Timeliness in Managing and Reporting Abnormal Papanicolaou
Smear Results
Abstract
Background: Cervical cancer deaths have decreased significantly as a result of increased
cervical cancer screening rates (CDC, 2014); however, cervical cancer is the fifth most
common cancer in the U.S. and the second most common cancer for women in the world
(CDC, 2014; Spence, Goggin, & Franco, 2007). The majority of cervical cancer
prevention and reduction strategies are focused on increased screening; In addition to
screening, proper management of abnormal results is a key factor to appropriate and
timely intervention (Yabroff, Kerner, & Mandelblatt, 2000).
Purpose: The purpose of this scholarly project was to assess, standardize, and improve
the quality monitoring and management of abnormal cervical cancer screening results
within an integrated health care organization.
Goals: To standardize quality monitoring and reporting activities for the organization’s
abnormal Pap smear management program.
Project Design: Quality Improvement Initiative
Findings & Conclusions: Though the project was not able to meet several of its
objectives explored, it did standardize the quality monitoring process for the organization
and generated an electronic quality reporting tool. This tool is currently being used in the
Cervical Cancer Screening program to monitor performance and disseminate quality
metrics throughout the organization.
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Implications for Positive Social Change: Developing programs to improve management
of abnormal Pap smear results combined with national efforts to increase cervical cancer
screening can reduce disparities in cervical cancer deaths and achieve the Healthy People
2020 target for reducing the incidence of cervical cancer.
Key Words
Cervical Cancer; Cervical Cancer Screening; Pap Test; Pap Smear; Quality; Quality
Monitoring; Quality Improvement
Introduction
Adhering to recommended cervical cancer screening guidelines with cytology
(i.e. Pap smear or Pap test) has been shown to reduce the incidence of invasive cervical
cancer (Vaccarella, Lortet-Tieulent, Plummer, Franceschi, & Bray, 2013; Vesco et al.,
2011). Since 1955, there has been more than a 60% reduction in the incidence and death
rate of cervical cancer (National Institutes of Health [NIH], 2010). Despite the significant
decline in cervical cancer deaths over the last 40 years, more than 4,000 U.S. residents
die annually from this treatable disease. According to the Centers for Disease Control and
Prevention (CDC), in 2014, 12,109 women were diagnosed with cervical cancer and
4,092 women have died from the disease (CDC, 2014).
The majority of cervical cancer prevention and reduction strategies are focused on
increased screening; however, proper management of abnormal results is also a
contributing factor to appropriate and timely intervention (Yabroff, Kerner, &
Mandelblatt, 2000). Identification of abnormal results, performed well by most accredited
healthcare organizations, is only the first step in the screening process. The reduction in
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invasive cervical cancer is not possible without the next step: the appropriate follow-up
of these abnormalities (Spence, Goggin, & Franco, 2007).
Background
To satisfy requirements for my doctor of nursing practice (DNP) degree, I chose
to design and implement a quality-improvement project within a large integrated health
care organization. The purpose of the project was to assess, standardize, and improve the
quality monitoring and management of abnormal Pap smear results. The organization
selected for this project, hereafter referred to as A1 Organization (pseudonym), has a
robust, efficient, and effective cervical cancer screening program. Although the
organization outperforms most industry screening benchmarks, opportunities exist to
enhance their current program – including improving the timely notification of women
identified with abnormal Pap smears and identifying barriers to proper follow-up care.
Incorporating evidence-based quality performance measures into the quality monitoring
process helps organizations to sustain improvement activities, monitor effectiveness, and
enable additional quality improvement (Maheshwari & Janseen, 2013; McLaughlin,
2014).
A1 Organization has established guidelines to track abnormal results and ensure
timely follow-up; however, the current paper-based process for tracking quality was not
standardized across the organization at the start of this project. Quality reports were
completed by hand using a standard form, but monitoring and reporting of quality metrics
and performance was inconsistently done throughout the three regional service lines. In
addition, the current process monitored performance for the general patient population,
but did not stratify results based on patient demographics. This prevented the
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organization from monitoring performance in specific populations in order to identify
potential areas for improvement. An identified current practice problem, the need for
standardized performance monitoring in the site organization’s current abnormal Pap
smear results coordination program, was addressed by this project.
The objectives of the program were:
•

To standardize monitoring and reporting activities by electronically
incorporating current quality metrics for the organization’s abnormal Pap
smear management program using the electronic health record system

•

To develop a centrally managed electronic quality report of the organizationspecific quality metrics for abnormal Pap smear management

•

To explore the possibilities of stratifying performance outcomes based on
race, ethnicity, and age for future reporting opportunities

•

To improve timeliness of abnormal Pap smear notification and follow-up for
sites performing below quality measure targets through use of electronic
monthly and/or quarterly Pap Tracking quality reports

In order for programs to run effectively, it is important for organizations to have
access to current, real-time data. This allows stakeholders and managers to accurately
monitor performance and utilize the data to make decisions to improve performance and
satisfy program objective and goals (McLaughlin, 2014; Wyatt, 2004). Performance
reporting and monitoring allows for increased program transparency, increased
accountability of programs, and increased support for maintaining, expanding, or
restructuring programs (Inamdar, Kaplan, & Reynolds, 2002). Quality reports can be
used to identify the patterns within the program to help identify areas of excellence and
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diagnose areas that need improvement. Establishing timely tracking/response of abnormal
Pap smear results as a routinely monitored performance measure can help organizations
to improve their management of adequate follow-up (McLaughlin, 2014).
Theoretical Framework
Health care organizations should continuously evaluate established processes to
achieve the best outcomes possible. Total quality management theory (TQM) describes
“the continual method, techniques and technical of sustaining continuous quality
improvement” in order to improve the overall performance of a company (Bon &
Mustafa, 2013, p. 518). Grounded in the teachings of William Edwards Deming and
Deming’s theory of management, TQM provides a framework for continuous
performance improvement in all organizational areas and levels. TQM theory proposes a
holistic approach to quality improvement that encompasses three principles: Customer
focus, continuous improvement, and teamwork (Zehir, Ertosun, Zehir, & Muceldilli,
2012). Use of TQM as a framework for quality improvement has been shown to improve
quality performance and support innovation (Bon & Mustafa, 2013; Zehir, Ertosun,
Zehir, & Muceldilli, 2012).
Evidence-Based Practice Model
The project was implemented using the PDSA or Shewart cycle model. In today’s
rapidly changing health care landscape, more quality improvement tools are being used to
assist in implementing evidence-based interventions (Siriwardena, 2009). The evidencebased practice model, PDSA cycle, was used to guide this project. The PDSA model is a
quality improvement model that provides a simple, systematic approach to addressing a
performance problem (Kelly, 2011). Developed by Walter Shewhart and Edward
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Deming, the PDSA model has been used in the industrial field (Taylor et al., 2013).
PDSA stands for “Plan”, “Do”, “Study”, and “Act”, which are the four cyclical steps of
the model. The PDSA model is a useful tool in investigating current processes while
implementing evidence-based change in a rapid manner (Siriwardena, 2009). Kelly
(2013) advised answering three questions before implementing the PDSA model:
1. What are we trying to accomplish?
2. How will we know that a change is an improvement? and
3. What change can we make that will result in an improvement? (p. 141)
Methods
In this project, the intervention includes reviewing and/or redefining established
quality metrics, capturing the identified metrics from the organization-specific tracking
system, and incorporating metrics into an electronic performance quality report. While
leaders monitor the macro-level performance, gaps in care for certain populations may
not be visible in the aggregate results. As such, options were explored to determine if the
report can be stratified by demographics (e.g., race, age, geographic location, etc.)
selected by the organization to also monitor micro-level results. Stratifying quality
performance data by demographics can identify shortfalls in specific populations, even
when overall performance is satisfactory, and clearly present areas for improvement.
The anticipated outcome from the new process was that the transparency and
feedback offered by the new quality reports would positively impact overall performance
and lead to improvements for specific populations. The goals were to learn how the
program serves specific populations, identify potential areas for process improvement,
and achieve the stated performance goals for abnormal Pap smear management.
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The timeline for the project objectives are listed below:
•

Establish electronic monitoring of quality metrics (12 weeks)
o Evaluate Baseline Quality Improvement Data (7 days)
o Review/Edit/Confirm Quality Metrics for Pap Tracking Program (14 days)
o Collaborate with clinical quality team to create an electronic quality report
(6 weeks)
o Investigate options to stratify electronic report by demographics (9 weeks)

•

Demonstrate improvement in timeliness of abnormal Pap smear result
notification and follow-up (12 weeks)
o Communicate overview and purpose of new electronic Pap Tracking
Quality Report to Service Line (2 weeks)
o Implement electronic monthly quality reports (12 weeks)
o Perform chart reviews of site performing under target to identify possible
barriers to care coordination and opportunities for improvement (2 weeks)
o Evaluate outcomes post-intervention to demonstrate effectiveness (1
week)
Data Collection

Continuous data collection and concurrent data analysis are critical attributes for a
functional quality improvement program (Curcin et al., 2014). Also, systematic processes
to measure and track quality improvement processes can validate the effectiveness or
ineffectiveness of interventions as well as the sustainability (Varkey, Reller, & Resar,
2007). The data collected for this project were the quality metrics established by the
organization:
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1. The number of abnormal results that had not been reviewed after more than 30
and 60 days.
2. The number of patients during the previous 90 days who were notified, but still
had not returned for follow-up.
For this DNP project, data collection was conducted using the developed
electronic reports. Human subjects were not be used and no identifiable patient
information was included in these reports. A simple time-series study design was used to
measure and effects pre- and post-implementation of the electronic reports. This quasiexperimental research design was selected because a true experimental design would not
be feasible in this setting. A simple time-series design involves “the collection of data
over an extended period of time and the introduction of an experimental treatment during
the data collection process” (Terry, 2012, p. 76).
For this project, a single group pretest/posttest design was used. A baseline
measurement of quality data was obtained prior to implementation of the program using
the current process. Once the electronic report was created, quality data were measured in
the beginning and three months after implementing electronic quality reports. All data
were presented in aggregate form only.
Analysis Method
A two-sample t test was used to measure the differences in mean quality
outcomes before and after implementing electronic quality reports. A two-sample t test
analysis “makes inferences about the equality of two population means, based on two
sample means” (Polit, 2010, p. 133). Since the data involved comparing performance
outcomes of the same group pre- and post-intervention, a dependent groups t test was
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required. Because of time restraints related to project implementation, run charts were
used in addition to t tests to show the quality data trends over time.
Results
As part of the quality improvement initiative, key stakeholders within the Cervical
Cancer Surveillance Program (CCSP) resumed regular meetings to review the quality of
the program. I worked within the CCSP’s Regional Pap Quality Meeting to develop and
implement the approved DNP project. In reviewing A1 Organization’s process for quality
monitoring and reporting, I discovered that the different regions within the organization
were using the same quality metrics. However, each region was monitoring and reporting
data at different intervals. The group agreed to continue using the established quality
metrics and came to a consensus to generate quality data reports monthly for all regions.
I used the old quality metrics and reports to build a new electronically formatted
report to be used by the nurses in the program. For nursing leadership, a report was
created to show the data trends for up to one year at a time. The reports were designed to
improve ease of use and reduce errors by providing automatic calculations of percentages
and totals. They also automatically displayed the data with certain visual characteristics
to show the user immediately which centers did not met the threshold targets. An added
feature to the reports was that they automatically generated charts of the quality metrics
once the data were updated. This allowed for the nurses and leadership to visualize the
data trends for the month and over time.
Once the reports were created, they were presented at the Regional Pap Quality
and approved for use by its members. In order to analyze whether use of the newly
implemented electronic reports helped to improve timely outreach and follow-up, I

46

compared the quality data from the first and second quarter of 2016 to the data from the
reports generated in 2015. The reports were piloted in one of the three regions, so only
data from this region was used.
In comparing the data from the Open Items Report (OIR), the report of how soon
outreach was done on abnormal results, in 2015, the average compliance rate for all of
the medical centers combined was 98%. For 2016, this number decreased to 95%,
meaning that more medical centers were not meeting their goals and were notifying
patients more than 30 days after the results were first available. Comparing the Pending
Items Report (PIR) from 2015 to the first and second quarters of 2016, more medical
centers had patients that still had not received the appropriate follow-up for their
abnormal Pap smear results by 30 days after notification than had previously been in
2015. The data analysis did not support the project’s hypothesis that implementation of a
standardized electronic report tool will improve quality for this program.
Using the OIR and PIR data from 2015 and 2016, a two-sample t test was done to
analyze the results. Both t tests assumed unequal variances. Data sample from 12-months
total were used: six nonconsecutive months in 2015 and six consecutive months in 2016.
(Because the quality reports were not consistently run in 2015, only 6 months of data
were available.) For the OIR report (Table 1), the mean compliance was 98.4% for 2015
compared to 93.9%. The two-sample t test gave a t-statistic of 2.024 with 6 degrees of
freedom (df). Using a significance level (a) of 0.05, the p-value is .089 and the t-value for
the data is 2.447. The means that there was no statistical difference between the two data
samples. After performing a t test for the PIR report, the results were similar (Table 2).
The mean PIR compliance rate was 98.2% in 2015 and 95.1% in 2016. The t test statistic
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was 6.484 with a df of 10. With a = 0.05 and a p value of 7.04 and the critical value is
2.31. As a result, this also demonstrated no statistical difference in the means for the PIR
quality data. Because of time constraints and the small data sample, run charts (Tables 36) were created to show the overall trend in data from the previous year until May 2016.
The data trend for 2016 showed that compliance had dropped slightly from the previous
year. Overall, the results and data analysis did not support the objective of improving the
program’s quality scores.

Table 1
Data Analysis of Open Items Report (OIR)
OIR Data Analysis
t test: Two-Sample Assuming Unequal Variances
Sample Size
SEM

M
Variance
Observations
Hypothesized M Difference
df
t Statistic
P(T<=t) two-tail
t Critical two-tail

12
1.2429
2015
2016
Data
Data
0.984028 0.939583
0.000297 0.002596
6
6
0
6
2.024003
0.089403
2.446912
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Table 2
Data Analysis of the Pending Items Report (PIR)
PIR Data Analysis
t test: Two-Sample Assuming Unequal Variances
Sample Size

12

SEM
2015
Data
M
Variance
Observations
Hypothesized M Difference
df
t Statistic
P(T<=t) two-tail
t Critical two-tail

0.51484
2016
Data

0.981806 0.951111
5.96E-05 7.49E-05
6
6
0
10
6.483755
7.04E-05
2.228139
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Figure 1. Graph of the data trends for the monthly OIR compliance rate of each medical
center that reported in 2015. The OIR is the number of number of abnormal cervical
cancer screening results that were addressed (i.e., outreach) within 30 days or less.
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Figure 2. Graph of the data trends for the monthly OIR compliance rate of each medical
center that reported from January-June 2016. The OIR is the number of number of
abnormal cervical cancer screening results that were addressed (i.e., outreach) within 30
days or less.
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Figure 3. Graph of the data trends for the monthly PIR compliance rate of each medical
center that reported in 2015. The PIR is the number of number of abnormal cervical
cancer screening results that were addressed (i.e., outreach) by the health care team, but
were still awaiting appropriate follow-up (e.g., colposcopy, repeat pap, cryosurgery, etc.).
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Figure 4. Graph of the data trends for monthly PIR compliance rate of each medical
center that reported from January-June 2016. The PIR is the number of number of
abnormal cervical cancer screening results that were addressed (i.e., outreach) by the
health care team, but were still awaiting appropriate follow-up (e.g., colposcopy, repeat
pap, cryosurgery, etc.).
Discussion
Organizational decisions also had a negative effect on meeting one of the project
objectives. A1 Organization decided to phase out the outdated Pap smear results tracking
system that they currently use and build a new tracking program within their electronic
health record. The tentative go-live date for this new system is sometime in 2017.
Currently, the organization is still in the process of developing the new program and
working out kinks. Because of the impending plan to retire the presently used, but
outdated program, along with uncertainty regarding deployment of the new program and
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its capabilities, administrative leadership decided not to explore options for stratifying
data by patient demographics until the new system is launched.
Operational activities within the service line created another variable that affected
quality data. During the project, the organization launched an upgrade to the lab result
reports function of the electronic health record. The upgrade led to a delay in receiving
lab results, as this required an additional step to order the HPV test. This greatly impacted
the PTN’s workflow causing an increase in time to outreach and documentation of
follow-up. Additionally, because the pilot region was already using a different workflow
for pap tracking outreach than the other two regions, their nurses reported more
challenges with providing timely outreach after the upgrade, which led to a greater
impact on their quality outcomes. Although there were several operational and
departmental factors involved that had a possible negative effect on project outcomes, the
project benefited the organization by creating a useful tool to monitor quality data and by
standardizing and facilitating quality improvement activities across the three service
areas. It is my professional opinion that with more time to monitor and collect data, the
project will lead to significant improvement on overall quality metrics.
Strengths and Limitations of the Project
This project was deemed a quality-improvement project by the site organization
IRB and received an expedited approval. Although the quality meetings were
reestablished and the information was shared across the organization, the quality tool was
piloted in one service area to allow for faster implementation and evaluation. The
electronic reports, while not showing an initial positive effect on quality outcomes,
allowed the quality workgroup to review data trends (short-term and long-term) and
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quickly identify sites that may need a more detailed investigation to determine possible
barriers or areas for improvement.
A limitation noted in this project was inconsistent monitoring conducted by the
region selected. As a result, the service area had data missing for several months. Another
limitation noted was related to the current monitoring system, which did not allow for
reports to be run on past data. I was left to complete the analysis with data from only six
months of the previous year and compare it to data from the first six months of 2016.
Since the 2015 data were incomplete, it was difficult to ascertain the potential impact of
the missing data on the project outcomes. Because of time constraints related to the IRB
approval, the collection and analysis of data was done relatively quickly. In my
professional opinion, time was a significant limitation in demonstrating a meaningful
impact on improving quality metrics after implementation of the reporting tool.
Conclusion
Cervical cancer, while on a steady decline since implementing routine cervical
cancer screening in the United States, continues to affect thousands of women and results
in hundreds of preventable deaths each year (CDC, 2014; Vesco et al., 2011)). Screening
for cervical cancer, while arguably the most important step in preventing invasive
cervical cancer, is not effective alone. Appropriate follow-ups, such as colposcopies, are
needed to address any detected abnormalities and prevent progression to invasive disease
(Spence, Goggin, & Franco, 2007). While the target health care organization for this
project has long utilized a system to ensure timely notification and intervention for
abnormal cervical cancer screening results, the quality and performance of the program
was not being consistently monitored across the board.
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The purpose of this project was to standardize the program’s quality metrics and
monitoring, explore capabilities for stratifying the quality data by patient demographics,
develop an electronic quality reporting tool to be used throughout the organization, and
improve timeliness of follow-up for abnormal cervical cancer screening results.
Implementation of the project was limited by time constraints and major program
changes within the organization. Although the project was not able to explore the
possibility of separating data based on patient demographics and did not demonstrate an
improvement in the quality scores, it resulted in standardized quality monitoring practices
throughout the program and helped to improve compliance with nursing quality
protocols.
The project also created an electronic quality-reporting tool to be utilized in all
regions. This tool will be centrally managed and can be easily shared within the program,
distributed across the service line, and disseminated out to executive leadership. Overall,
this type of quality-improvement project can be used as a model with other population
care-based programs to establish and evaluate quality metrics and monitoring procedures
to be employed as a way to promote continuous quality improvement in any health care
setting.
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